15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Solid Biosciences LLC, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $12.00 to $26.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $18.71 sits 135% above the current $7.96. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.48 next quarter toward $-1.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Solid Biosciences LLC.
As of Jul, 9 of 9 firms rate SLDB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SLDB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.48
Range $-0.57 – $-0.39 · 13 analysts · -1% YoY
Next period, 13 analysts expect Solid Biosciences LLC to earn $-0.48 a share (range $-0.57 – $-0.39), versus $-0.48 a year earlier. Full-year consensus is $-1.96, growing to $-1.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 13 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.1M next year.
Top analysts covering Solid Biosciences LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SLDB.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$15.00+88.4% to target
Overall win rate
50%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Buy
$12.00+50.8% to target
Overall win rate
46%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #100
Buy
$15.00+88.4% to target
Overall win rate
44%
+ Follow
#4
Laura Chico
Wedbush · Rank #122
Buy
$16.00+101.0% to target
Overall win rate
40%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$14.00+75.9% to target
Overall win rate
43%
+ Follow
SLDB stock forecast FAQ
What is SLDB's average 12-month price target?+
The 7 analysts with a live target average $18.71 for Solid Biosciences LLC over the next 12 months, ranging from a $26.00 high to a $12.00 low.
Is SLDB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SLDB?+
The Street-high target is $26.00 (Guggenheim), and the Street-low is $12.00 (JP Morgan). The average of all 7 active targets is $18.71.
How many Wall Street analysts cover SLDB?+
9 analysts have an active rating on Solid Biosciences LLC, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering SLDB?+
Among analysts who currently cover SLDB, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $15.00 target.
What is Solid Biosciences LLC's projected EPS for next quarter?+
The consensus estimate is $-0.48 per share (range $-0.57 – $-0.39) across 13 analysts. Full-year EPS is projected at $-1.96, rising to $-1.96 the following year.
How much revenue is Solid Biosciences LLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.1M next year.
Have analysts been upgrading or downgrading SLDB lately?+
As of Jul, 9 of 9 firms rate SLDB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SLDB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
